Lifeloc Technologies (LCTC) AI Stock Analysis

• Market Cap: $8.57M
• Dividend Yield: N/A
• Average Volume (3M): 387.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.06
• Revenue Growth: -7.05%
• EPS Growth: -4022.22%
• Country: US
• Employees: 39
• Sector: Technology
• Sector Strength: 78
• Industry: Hardware, Equipment & Parts
• EPS (TTM): -0.11
• Shares Outstanding: 2,752,616
• 10 Day Avg. Volume: 860
• 30 Day Avg. Volume: 387
• PEG Ratio: -3.22
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -96.58
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 0.19
• Enterprise Value/Gross Profit: 1.94
• Enterprise Value/Ebitda: -1.89
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: $3.00 ▼( -3.85% Downside)

Lifeloc Technologies faces significant challenges with weak financial performance and bearish technical signals. The negative P/E ratio and lack of dividend yield further weigh down the stock's attractiveness. Improvement in operational efficiency and cash flow management is crucial for future stability.

Lifeloc Technologies Business Overview & Revenue Model

Company Description

Lifeloc Technologies (LCTC) is a leading American company specializing in the development and manufacturing of breath alcohol testing equipment and related software. The company operates in the safety and security sectors, providing innovative alcohol testing solutions for law enforcement, workplace, and personal use. Lifeloc Technologies is recognized for its high-quality breathalyzers, calibration equipment, and software designed to ensure accurate and reliable alcohol testing results.

How the Company Makes Money

Lifeloc Technologies generates revenue primarily through the sale of its breath alcohol testing equipment and related products. The company's key revenue streams include direct sales to law enforcement agencies, workplace safety programs, and individual consumers. Additionally, Lifeloc offers calibration and training services to ensure the proper use and maintenance of its equipment, providing an ongoing revenue stream. Significant partnerships with governmental and private organizations also contribute to its earnings, expanding its market reach and enhancing its product offerings.

Lifeloc Technologies Financial Statement Overview

Summary

Overall, Lifeloc Technologies faces challenges with profitability and cash flow management, despite maintaining a resilient balance sheet. The company needs to improve operational efficiency and strategic cash flow management to enhance financial stability and performance.

Income Statement

Lifeloc Technologies shows weak performance in its income statement with a declining revenue trend from 2023 to TTM. The gross profit margin is moderate but overshadowed by negative net and EBIT margins, indicating operational inefficiencies and losses. The company has struggled with consistent negative net income over the periods.

Balance Sheet

The balance sheet remains relatively stable with a high equity ratio and manageable debt levels. Debt-to-equity ratio is low, reflecting conservative leverage strategy. However, the return on equity is negative due to ongoing losses, indicating inefficiencies in generating returns from equity investments.

Cash Flow

Cash flow analysis reveals volatility with a recent positive shift in operating cash flow for TTM, a positive indicator. However, free cash flow remains negative, highlighting potential liquidity challenges. The operating cash flow to net income ratio shows improvement, but overall cash flow management needs enhancement.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
8.66M	8.54M	9.33M	8.48M	7.05M	6.36M
	Gross Profit
3.52M	3.45M	4.04M	3.07M	3.06M	2.18M
	EBIT
-1.31M	-1.41M	-191.13K	-529.66K	-268.91K	-1.16M
	EBITDA
-1.04M	-1.07M	139.45K	98.46K	-2.02K	-777.96K
	Net Income Common Stockholders
-1.06M	-1.05M	205.61K	-455.76K	675.97K	-921.93K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.05M	1.24M	1.77M	2.35M	2.57M	2.20M
	Total Assets
8.36M	8.72M	8.69M	8.52M	8.95M	8.54M
	Total Debt
1.26M	1.80M	1.22M	1.27M	1.32M	1.79M
	Net Debt
-794.56K	558.60K	-544.79K	-1.08M	-1.26M	-405.51K
	Total Liabilities
2.26M	2.50M	2.33M	2.36M	2.36M	2.64M
	Stockholders Equity
6.10M	6.23M	6.36M	6.16M	6.59M	5.90M
Cash Flow		Free Cash Flow
-86.07K	-2.02M	-533.96K	-168.25K	-85.53K	-1.41M
	Operating Cash Flow
353.91K	-1.33M	-525.74K	54.33K	182.94K	-1.36M
	Investing Cash Flow
-627.86K	-689.45K	-8.21K	-222.58K	-268.48K	-46.27K
	Financing Cash Flow
1.91M	1.49M	-52.18K	-50.66K	462.13K	419.13K

Lifeloc Technologies Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LCTC, the sentiment is Neutral. The current price of 3.12 is above the 20-day moving average (MA) of 3.09, below the 50-day MA of 3.14, and below the 200-day MA of 3.58, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 51.52 is Neutral, neither overbought nor oversold. The STOCH value of 53.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LCTC.

Lifeloc Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$11.28B	10.16	-6.88%	2.97%	7.41%	-8.93%
LCTC	45 Neutral	$8.57M	―	-17.18%	―	-7.05%	-4022.22%
SLNH	43 Neutral	$9.89M	―	-2402.49%	―	2.87%	47.47%
WATT	38 Underperform	$9.54M	―	-182.14%	―	137.14%	57.43%

Lifeloc Technologies Corporate Events

Lifeloc Technologies Secures Financing for Innovative Growth

Lifeloc Technologies has secured $750,000 in financing through a subordinated debenture agreement with Diamond Bridge Capital, aimed at supporting growth initiatives and the commercialization of its SpinDx technology, which promises rapid, cost-effective drug testing. This funding reflects confidence in Lifeloc’s business model and supports its strategy of expanding its product offerings, with plans to integrate SpinDx with their existing alcohol breathalyzer products to develop a marijuana breathalyzer, thus enhancing their market presence and innovation capabilities.